Search for a trial

A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD) (CRFB002ADE23, SALT study)

Primary: to compare the treatment effect of ranibizumab PRN (visual acuity loss and/or SD-OCT disease activity guided retreatment) versus aflibercept bimonthly regimen on central retinal thickness stability as measured by mean fluctuations between…

A phase IIIB, one year, open label, multicentre, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium injection in subjects with diabetic macular edema (DME)

The primary objective of this study is to further evaluate the safety and tolerability of pegaptanib sodium in subjects with DME.

Safety, Tolerability and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration

To assess the safety, tolerability and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared to Lucentis in patients with exudative AMD

Comparison of the effects of phenylephrine and norepinephrine on hemodynamics and tissue oxygenation in patients undergoing ophthalmic surgery.

Determine whether phenylephrine or norepinephrine has superior haemodynamical effects in ophtalmic surgery

Navilas* laser versus classic frequency doubled Nd-YAG (532 nm) laser therapy for diabetic macular edema. A randomized study analyzing the effect on central visual function.

To study the impact of laser photocoagulation on the parafoveal visual field in a previously untreated population of patients with DME.

Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum.

The main objective is to determine if bisphosphonate therapy with etidronate leads to stabilization or attenuation of ongoing calcification in the leg arteries as quantified by 18F-sodium fluoride(18F-NaF) PET-CT imaging in patients with PXE.…

E-mental health intervention for patients with exudative retinal diseases who receive intraocular anti-VEGF injections (E-PsEYE) - pilot study

To investigate if E-PsEYE leads to a reduction in depression and anxiety symptoms (primary outcomes) and problems with adaptation to vision loss(secondary outcome). Conducting a process evaluation to determine adherence and patient satisfaction. To…

Follow up after Treated Circumscribed Choroidal Haemangioma with Photodynamic Therapy

Long-term follow up of patients treated with limited PDT, for a symptomatic circumscribed choroidal hamangioma, in search of possible late unwanted side effects of PDT treatment and recurrence of leakage.

Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal SErum IGF-I Levels within Physiological Levels in Premature Infants, to prevent Retinopathy of Prematurity;A Phase II, Randomized Controlled, Assessor-Blind, Dose-Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study

To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for GA at birth while confirming the dose of rhIGF 1/rhIGFBP-3 is safe and efficacious.

An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular
edema in patients who have completed the RESTORE trial

Primary objective* To evaluate ocular and non-ocular adverse events during the 24-months study period in patients treated with Lucentis (0.5 mg)Secondary objectives* To describe the ocular and non-ocular adverse events over a cumulative 36-months…

A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Diabetic Macular Edema.

The purpose of this study is to evaluate if microplasmin is safe and effective when injected into the vitreous without performing a vitrectomy.

Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.

To compare visual outcome and foveal function after (initiation of) treatment between patients receiving an RPE-choroid graft and patients with anti-VEGF medication.

A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema

Primary objectiveto demonstrate superiority of ranibizumab 0.5 mg as adjunctive or mono-therapy to laser treatment in the mean change from baseline in BCVA over a 12-month treatment period.Secondary objectives* to evaluate whether ranibizumab (0.5…

Are elevated prolactin levels harmful for the retinal and sublingual microvascular bed?

Primary objective: To evaluate whether patients with a prolactinoma have signs of altered vascular function and/or morphology in the retina or sublingual tissues in comparison to healthy controls. Secondary Objectives: 1. To evaluate whether there…

Long-term follow-up and cross-over of treatment with high-density micropulse laser and half-dose photodynamic therapy in participants of the PLACE trial for chronic central serous chorioretinopathy.

Primary objectives:- To investigate the long-term outcome after successful treatment (no subretinal fluid on OCT) in the PLACE trial.- To investigate whether a cross-over treatment of half-dose PDT to HSML in cCSC patients who either did not respond…

A prospective randomised controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (CSC).

Primary ObjectiveTo investigate whether half-dose PDT treatment leads to a higher percentage of chronic CSC patients with subretinal fluid on OCT achieving an absence of this subretinal fluid on OCT as compared to HSML treatment.Secondary…

A 24-month, phase IIIb, open-label, randomized, active-controlled,
3-arm, multicenter study assessing the efficacy and safety of an individualized,
stabilization-criteria-driven pro re nata (PRN) dosing regimen with 0.5-mg
ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser
photocoagulation in comparison to laser photocoagulation in patients with visual
impairment due to macular edema secondary to branch retinal vein occlusion
(BRVO)

Primary objective:To demonstrate that an individualized stabilization-criteria-driven PRN dosingregimen (PRN) with 0.5-mg ranibizumab administered with or without adjunctive lasertreatment has superior efficacy as compared to the current standard of…

A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the
efficacy and safety of an individualized, stabilization criteria-driven pro re rata (PRN) dosing regimen
with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual
impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

The primary objective is to evaluate the efficacy of an individualized stabilization criteriadrivenPRN dosing regimen with 0.5 mg ranibizumab as assessed by the mean best-corrected visualacuity (BCVA) change at Month 12 compared to Baseline.

A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME) (CRFB002G2302)

Primary: To demonstrate that intravitreal injection of 0.5 mg ranibizumab administered based on individual patient needs has superior efficacy compared to sham treatment in adult patients with visual impairment due to VEGF-driven ME. Secondary: Best…

Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)

The objective of this study is to observe the anatomical and functional outcomes of ocriplasmin over a 6-month follow-up period.